New research shows how Optimer can speed projects by up to 75% compared to standard antibodies. Speeding project timelines can be vital to the development of any life science product. Whether…

The genomic revolution brought simple, sensitive and rapid DNA sequencing, creating a step-change in our biological understanding. Next-generation proteomics is now promising to do the same for protein sequencing…

Modified thymine bases, each containing a polymerizable group (either carboxymethylvinyl or acrylamide) at the 5-position, have been incorporated multiple times into an aptamer sequence allowing the sequence to act…

Last week the government released their new Life Sciences Vision. This 10-year strategy for the sector aims to ensure that the United Kingdom builds a supportive environment for…

Life at Aptamer Group and top tips for success in Optimer binder development In this interview, we speak with Harriet Flynn, Production Manager at Aptamer Group. From starting as…

04/03/2021 Aptamer Group, the developer of Optimer™ reagents and therapeutics, today announced the extension of their current agreement with AstraZeneca, a global biopharmaceutical company. This agreement will build upon the existing…

At Aptamer Group, we’re determined to provide our customers and partners with the highest quality service. We’re excited to announce our new branding to reflect our commitment to…